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Background: In an effort to control non-medical use and/or medical abuse of prescription drugs, particularly
prescription opioids, electronic prescription drug monitoring programs (PDMP) have been introduced in
North-American countries, Australia and some parts of Europe. Paradoxically, there are simultaneous pressures to
increase opioid prescribing for the benefit of individual patients and to reduce it for the sake of public health, and this
pressure warrants a delicate balance of appropriate therapeutic uses of these drugs with the risk of developing
dependence. This article discusses pros and cons of PDMP in reducing diversion of prescription opioids, without
hampering access to those medications for those with genuine needs, and highlights tensions around PDMP
implementation.
Discussion: PDMPs may help alleviate diversion, over-prescription and fraudulent prescribing/dispensing; prompt drug
treatment referrals; avoid awkward drug urine test; and inform spatial changes in prescribing practices and help
designing tailored interventions. Fear of legal retribution, privacy and data security, potential confusion about addiction
and pseudo-addiction, and potential undue pressure of detecting misuse/diversion - are the major problems. There are
tensions about unintended consequence of excessive regulatory enforcements, corresponding collateral damages
particularly about inadequate prescribing for patients with genuine needs, and mandatory consultation requirements
of PDMP.
Summary: In this era of information technology PDMP is likely to flourish and remain with us for a long time. A clear
standard of practice against which physicians’ care will be judged may expedite the utilisation of PDMP. In addition,
adequate training on addiction and pain management along with public awareness, point-of-supply data entry from
pharmacy, point-of-care real-time access to data, increasing access to addiction treatment and appropriate regulatory
enforcement preferably through healthcare administration, together, may help remove barriers to PDMP use.
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In an effort to control non-medical use and/or medical
abuse of prescription drugs, particularly prescription
opioids and benzodiazepines, prescription drug moni-
toring programmes (PDMP) have been introduced in
North-American countries, Australia and some parts of
Europe. Although the history of PDMP goes back to the
early twentieth century [1] an increasing non-medical
use and/or medical abuse of controlled drugs and* Correspondence: mofizul.islam@anu.edu.au
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article, unless otherwise stated.associated deaths observed in recent times, and the
computerisation of PDMP, have brought it back into
focus. Ironically, there are simultaneous pressures to in-
crease opioid prescribing for the benefit of individual
patients and to reduce it for the sake of public health
[2]. This dilemma puts increasing pressure on policy
makers to balance appropriate therapeutic uses of these
drugs with the risk of developing dependence, abuse
and fatality from overdose.
Although programme specifics vary across settings, gen-
erally electronic PDMPs require retail pharmacists to
enter data from prescriptions for controlled substances
into a centralised electronic database. These data identifyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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dose, and amount dispensed. Some PDMPs require add-
itional information which helps pharmacists/prescribers to
track and identify duplicates and stolen forms [3]. The ini-
tial purpose of PDMP was to detect and reduce diversion,
abuse, and misuse of prescription medications classified as
controlled substances, and to reduce associated harms,
although a PDMP can of course also be used to provide
information to enable physicians to offer more appropriate
care. The aim of this article is to discuss, based upon the
available literature, the pros and cons of PDMP in achieving
the overarching goal of reducing inappropriate prescribing,
particularly of opioids (while the discussion in this paper re-
lates to other controlled substances, the paper will focus on
opioids), without hampering access to essential medications
for those with genuine needs.
Pros
Reduce over prescription and doctor shopping
In day-to-day clinical practice it may be difficult to dis-
cern a patient who legitimately suffers pain from one
who is pretending to be in pain for the sake of obtaining
drugs. Inappropriate prescribing of controlled sub-
stances, particularly those prescribed as pain killers, can
arise where a patient pretends to have pain or amplifies
pain. One dimension is to identify those who either ini-
tially through pain management or through other routes
developed dependence and are using multiple medical
providers in order to abuse prescription pharmaceuti-
cals. Pain is a condition that is almost impossible to
measure from laboratory tests, radiologic imaging, or
physical examination, physicians rely largely on patient
interviews and histories, depend on interpretation of
what they see and hear [4]. PDMPs can add accuracy to
providers’ clinical judgments to determine the require-
ments for pain management.
A PDMP will inform a physician if a patient has
recently accessed opioids elsewhere. This will help to
identify doctor shoppers (or prescription shoppers), or
persons who have no genuine medical need. By identify-
ing these patients, a real-time PDMP may help alleviate
over-provision and potentially diversion of these phar-
maceuticals. As an added benefit, prescribers may moni-
tor the database to detect forged prescriptions or stolen
prescription pads/pages [2].
Reduce fraudulent prescribing by physicians
In addition to addressing issues of patients, PDMPs can
help to identify any suspected fraudulent prescribing or il-
legal activity related to the dispensing of controlled sub-
stances, and inform the professional licensing boards of
these clinicians. In Florida, for example, PDMP played an
important role in the improvements in its prescription
drug-abuse record. In 2010, among the top 100 oxycodonepurchasing physicians in the nation 90 were located in
Florida. This number dropped to only 13 in 2011.
Quality of care
A different but arguably more important aspect of the use
of PDMPs is that the provision of up-to-date information
about controlled substance use across all practices and
physician’s access to that information can support clinical
judgement and improve the quality of care. PDMP can
help identify patients who are receiving multiple legitimate
prescriptions but are at risk of complications from poly-
pharmacy [2].
Health professionals’ access to a real-time PDMP may
facilitate a patient-centred approach to addressing pre-
scription drug abuse. It is more comfortable checking a
PDMP report than mandating urine drug screening,
which can result in disruption of the patient-physician
relationship [5]. Furthermore, patients’ awareness of the
PDMP database may lead them to provide information
which would enhance the patient-provider relationship.
PDMP may help identify those at highest risk for opioid
overdose and so create an opportunity for intervention
when aberrant behaviour is first noted [2]. A survey in
Maine, USA found PDMP helped over a third of the pre-
scribers referring their patients to substance abuse treat-
ment [6].
Real-time access to a patient’s prescription history
increases prescriber’s confidence in prescribing. For in-
stance, a study of real-time PDMP in an emergency de-
partment in Ohio found that after reviewing the patient’s
prescription history clinicians changed their opioid pre-
scription in 41% of cases, of which more than a third
(39%) received higher doses than initially planned [7].
Geographic trends of use
PDMPs contain a wealth of information about the demo-
graphic trends and types of prescription drug use, poison-
ing and overdose which may be analysed to reveal changes
in prescribing practices and patterns that are shaping the
evolving trends. Data from prescription monitoring pro-
grammes may also be used to identify geographic areas
with high rates of opioid misuse, allowing the introduction
of focused interventions in those communities. Such an
approach could improve the reach of existing preventive
and/or associated programmes [8].
Cons and tensions
Physician concerns
There is concern among some physicians who for valid
reasons are relatively high prescribers that if they are
identified by a PDMP they may be seen to be prescrib-
ing inappropriately. While most physicians would be
expected to support interventions to prevent fraudulent
prescribing, high profile criminal prosecutions of physicians
Islam and McRae BMC Pharmacology and Toxicology 2014, 15:46 Page 3 of 7
http://www.biomedcentral.com/2050-6511/15/46prescribing large amounts of opioids in USA [9,10]
could make the physicians reluctant to prescribe con-
trolled substances for fear of legal retribution (“chilling
effect”) [1]. Although formal research on the chilling
effect is rare, surveys indicate that some prescribers
underutilise controlled substances due to fear of legal
repercussions [11-13]. There is greater perceived legal
risk for prescribing/dispensing too much pain medica-
tion than for prescribing/dispensing too little pain
medication [14].
The chilling effect could also lead to increased prescrib-
ing of alternate medications (substitution effect), even if
they are inferior in terms of effectiveness or have greater
side effects. Many of these alternate medications are uncon-
trolled medications – as was noted when benzodiazepines
were added to in New York’s paper-based prescription
monitoring registry in 1989 [15]. Another example is in-
creased prescribing of Schedule III opioids in California
after it removed the triplicate prescription system in order
to reduce prescribing of Schedule II drugs [9].
Pseudo addicts
A PDMP may deter legitimate prescribing for a patient with
a history of receiving pain medication from several physi-
cians. Such patients may be “pseudo-addicts” whose pain
has not been controlled by sub-therapeutic analgesics doses
and who is genuinely seeking relief of pain, not support of
an addiction [16].
Patient concerns about refusal to prescription and
consequences
Like prescribers, patients may fear coming under scrutiny
from law-enforcement if they use medications monitored
by the PDMP. Patients may worry about the additional cost
of more frequent office visits if prescribers become more
cautious about writing prescriptions with refills [15]. Pa-
tients who are questioned about substance use and then ex-
cluded from an expected treatment may feel embarrassed
or abandoned. PDMP can produce pressure on physicians/
pharmacists to detect and respond to suspected misuse/di-
version and this may negatively impact on service rapport
and trust. Patients who have a history (past or present) of
opioid dependency are at risk of not obtaining the treat-
ment for valid conditions [17]. These can result in people
not returning to the physicians for on-going care. There is
concern that this refusal could eventually push some pa-
tients into the illicit market [18]. For instance, the opioid
abuse crackdown in Florida has been followed by an indica-
tion of increased use of heroin, and overdose presentation
in the emergency department [19].
Wrongful categorisation as fraudulent prescribers
Many practicing physicians have little if any formal train-
ing to enable them to identify prescription drug abuse orrecognise the warning signs of drug diversion. In USA
over 40% of primary care physicians report difficulty in
discussing the possibility of prescription medication abuse
with patients and over 90% fail to detect symptoms of sub-
stance abuse [20]. Amid these knowledge-gaps and diffi-
culties PDMPs may wrongfully suspect and categorise
some conscientious and caring physicians as fraudulent
prescribers when they are actually prescribing in good
faith but lack training.
Privacy
There is discomfort among physicians and patients that
PDMP means that a medical consultation is no longer a
private affair, and raises concerns about maintaining pa-
tient/provider privacy, confidentiality and data security.
Data entry from a huge network of pharmacies and staff
access to the database make the system susceptible to un-
scrupulous use and data leaking. Already there have been
some incidences of privacy breaches. The Florida database
which leaked the personal information of thousands of pa-
tients who were reportedly not all relevant to county pros-
ecutors investigating a criminal case, is one such example
[21]. Privacy concern may also lead some patients to avoid
or to postpone needed medication for fear of being la-
belled as drug addicts. Both American Medical Associ-
ation and American Society of Addiction Medicine stress
the need to treat PDMP information just as well as, if not
better than, any other medical record [22,23].
Law-enforcement or healthcare?
Recognition of prescription drug abuse has evoked
many regulatory and legislative actions, and in some set-
tings healthcare policy is increasingly influenced by law-
enforcement agencies. By their nature, law-enforcement
agencies will focus on the abuse side of the equation,
without always considering any detrimental effect from
inadequate prescribing. The abuse of prescription drugs
is a multifaceted problem and needs collaboration of
various stakeholders. Abuse of these drugs is more of a
public health issue than anything else, and requires a
public health focus – as opposed to a strictly law-
enforcement focus [24]. However, in some settings with
origins in law-enforcement, PDMPs are seen as a tool of
the police rather than an important component of pa-
tient safety. With that police tool in mind many doctors
see PDMP as a thinly veiled means of police looking
over their shoulders and have fear of coming under
scrutiny by law enforcement agencies [25]. Such a scru-
tiny to doctors, who for legitimate reasons need to
prescribe large amount of opioids even if these are ap-
propriate, is definitely a nuisance. The American Med-
ical Association supports PDMP programmes being
housed with a state agency whose primary purpose is
health care quality and safety.
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It is recognised that dichotomisation of users into ‘pain pa-
tients’ and ‘illicit users’ is an oversimplification of a complex
issue, and there is overlap between these two groups [26].
The size of the population who experience chronic pain is
quite large; in USA alone it is approximately 100 million
[27]. Opioid dependence has been estimated to affect over
one-third of patients with chronic pain [28]. While PDMP
may help physicians in identifying and treating patients
with dependence, there is a huge challenge in treating
concurrent opioid dependence and pain, and finding the
balance between minimising risks and negative conse-
quences of opioid use whilst not reducing effective pain
treatment [29]. Referring patients for dependence treatment
has also major impediments as treatment systems are
largely developed for illicit drug users, and are not suitable
for a other groups [18].
Mandatory use of PDMP, time demands and patient
satisfaction
PDMP consultation may create additional time pressure
on physicians. Identification of potential abuse warrants a
series of responses including counselling and referral for
substance abuse treatment – which are also time demand-
ing. Amid these pressures, encouraging physicians to use
PDMP databases in settings where it is voluntary has been
a challenge, part of which relates to making the databases
more convenient for physicians that include real-time data
provision, easy recovery of forgotten passwords [6] and
easy navigation to the web portal [2]. There is proposal to
apply mandatory consultation requirements in certain
cases, for instance, when the physician needs to prescribe
certain quantity of medication or to a certain group ofTable 1 Potential benefits, unintended consequences and ten
Pros
▪ Informed and safe prescribing for patients. ▪ P
l
▪ An appropriately programed real-time PDMP is likely to reduce pre-
scription drug diversion, doctor shopping, and related casualties.
▪ C
i
▪ Reduction of overprescribing by the physicians. ▪ M
c
o
▪ Reduced risk of complications from polypharmacy. ▪ P
a
▪ Help avoiding awkward patient confrontation such as urine drug









▪ Help reducing fraudulent prescribing and inform the professional
licensing boards about inappropriate prescribing/dispensing.
▪ P
▪ May reveal changes in prescribing practices and patterns, and spatial
information in small geographical area may inform tailored
intervention.
▪ Mpatients [30]. However, this may lead some providers to
discontinue or further cut back on controlled substance
prescribing. There is also tension around PDMP-driven
patient dissatisfaction. Doctors who refuse to prescribe
opioids to certain patients out of concern about abuse are
likely to get a poor survey-ratings, which can affect physi-
cians’ reimbursement and job security [4] (Table 1).
Discussion
While there are a range of advantages and disadvantages
to PDMP systems from a public health perspective, given
the perceived benefits of these systems to law enforce-
ment, to health regulators, and to public and private
funders of health care, in conjunction with the trends to
various forms of electronic patient records which facili-
tate the extraction of the necessary data, it seems likely
that PDMP will remain and probably expand over time.
In these circumstances the public health endeavour will
be to find a balance which ensures the health gains from
access to this information more than offsets any health
losses from physician or patient reaction to the systems.
The reduction of substance abuse and the promotion
of effective pain management are both equally import-
ant objective. However, a very small proportion of pa-
tients are involved in drug diversion/abuse; according to
a recent study only 0.7% of patients obtained their pre-
scriptions from a suspiciously large number of different
prescribers [31]. Thus in evaluating a PDMP one must
also consider how many patients with genuine needs
of pain medications have not been prescribed – the
literature consistently shows multiple-copy prescription
monitoring programmes reduced access to pain medica-
tion for patients with genuine needs [32].sions around PDMP
Cons and tensions
atient may not receive sufficient medications due to physicians’ fear of
egal retribution (“chilling effect”).
hilling effect may influence increased prescribing of inappropriate or
nadequate alternate medications (substitution effect).
ay deter legitimate prescribing by creating confusion between the
oncepts of addiction and pseudo-addiction, and in treating patients with
pioid dependence and pain.
atients may fear of coming under scrutiny by law enforcement agencies
nd be deprived from medications.
DMP-induced reduction of prescription opioids may increase crime par-
icularly among illicit drug users, and push some pain patients into the
llicit market.
ear among the physicians of being categorised as fraudulent prescribers
hen they are actually prescribing in good faith but lack training.
rivacy concern and data security.
ay negatively impact on service rapport and trust.
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mensional problem. While there are no simple solutions
for effective prevention, some measures could be taken
immediately. One such measure is to offer up-do-date
information to that section of providers who have insuffi-
cient knowledge about PDMP and prescription drug ad-
diction. This issue can be addressed through medical
education curriculum and continuing programs for the
physicians and pharmacists. Physicians’ willingness to fill
their knowledge-gap about prescription opioids and PDMP
are well recorded in the literature [20,33,34]. Another
measure is to educate patients about prescription opioids,
their appropriate use, potential risks and proper disposal
techniques, and the necessity and importance of PDMP in
prescribing opioids. Physicians are better placed to do that
comfortably.
Improving the existing PDMPs to real-time programs
is another highly recommended measure. Physicians and
pharmacists who currently use PDMP or are willing to
use this program often report its lack of real-time data
provision. Unfortunately only in few settings authorities
could ensure a real-time data transmission at the point
of dispensing. Currently, the most common time frame
for data transmission is ranging from monthly to daily
[30]. In fact, as demonstrated in British Columbia, the
usefulness of a PDMP, to a large extent, is attributable to
the speed of its data collection [35].
A major driver of the risk of use of PDMPs leading to
under-prescribing is the threat of patients or physicians
being pursued by law-enforcement officials. These con-
cerns will largely be mitigated if clear standards of prac-
tice against which physicians’ care will be judged are
available, and if enforcement is seen as appropriate. The
first round of response to any perceived misuse should
be undertaken by healthcare administrations and these
concerns should be only passed on to law-enforcement
authorities after investigation by the healthcare bodies.
Such an approach is likely to alleviate some pressures on
physicians and patients and address some concerns
about privacy, although not completely. This comprom-
ise about privacy is perhaps a necessary cost to prevent
unscrupulous demand, prescribing or dispensing, and
highlights that the duty of care may override such priv-
acy considerations [36] Strong data security and privacy
measures must be in place and be known to be in place.
Law-enforcement agencies should not have access to pa-
tient specific PDMP data unless they have an active in-
vestigation, and healthcare providers should only have
access to data relevant of their patients [37].
Data regarding the overall effects of electronic PDMPs,
and in particular in relation to the balance of impacts on
over and underutilisation, are limited, with aggregate stud-
ies tending to show little impact, and more qualitative stud-
ies tending to show participants do believe the PDMPshave an impact on behaviour. One American study found
no difference in the incidence of opioid overdose mortality
between states with and without PDMPs, and PDMPs’ ef-
fect on overall consumption of opioids appeared to be
minimal [3]. Surveys of prescribers, pharmacists, and law-
enforcement officials who use PDMP suggest that it is help-
ful in curbing abuse and diversion [32]. The few other
evaluations that have been conducted thus far have found
that the programmes are somewhat successful at reducing
diversion [1,35,38,39].
A recent study from Canada found no differences in
the opioid prescribing rate when comparing provinces
with and without PDMPs [40]. However, Simeone et al.
found PDMPs that issue reports proactively are likely to
change prescriber behaviour in a way that reduces per
capita supply of prescription pain relievers/stimulants,
“which in turn reduces the likelihood of abuse” [41]. Al-
though there is a correlation between overall supply and
the likelihood of misuse [42], it is unclear whether this
PDMP‐induced reduced supply translates into lower
levels of opioid related harms and problems or whether
there could have been both an increased under-
treatment of pain or both [18,43].
Given the international trends amidst an increasing
concern about abuse of prescription opioids, PDMPs are
likely to gain more ground and expand, and the current
reluctance among a portion of physicians/pharmacists to
PDMP use is likely to disappear over time. We have evi-
dence from similar events. When the supervised dis-
pensing of methadone was introduced in 1996 in the UK
some practitioners regarded it as an intrusion upon their
clinical autonomy, but in the decades since then pre-
scribers have followed the treatment guidelines [44].
In the discourse on PDMP, one thing often overlooked
is the information and communication technology break-
throughs, networking and internet that enable work to be
separated from time and space. The information technol-
ogy improvement is running so fast, people are being so
much habituated to it that, despite its problems, PDMP
will continue. However, this does not mean that everyone
will have to accept it passively. PDMP needs to be shaped
appropriately so that it caters the needs of providers and
patients. The sooner the prescribers and dispensers shape
the PDMP the way they want and embrace it, the better
the outcomes will be for their patients.
Conclusion
Despite some unintended consequences of PDMP, it is
likely to flourish and remain with us for a long time. Con-
tinued improvements in information technology may
work as a catalyst in PDMP proliferation. A clear standard
of practice against which physicians’ care will be judged
may expedite the utilisation of PDMP. In addition, ad-
equate training on addiction and pain management along
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awareness, point-of-supply data entry from pharmacy,
point-of-care real-time access to data, increasing access to
addiction treatment and recovery, appropriate enforce-
ment preferably through healthcare administration, to-
gether, may accelerate the acceptance and help realise the
full benefits of PDMP.
Abbreviations
PDMP: Prescription drug monitoring programme; USA: United States of
America; UK: United Kingdom.
Competing interests
The authors declare that they have no competing interests. The conclusions
and opinions expressed in this article are those of the authors and do not
necessarily reflect those of their respective organisations.
Authors’ contributions
MMI conceptualised the paper and undertook the literature review. Both
MMI and ISM were involved in acquisition and analysing the results and
drafting the manuscript. Both authors read and approved the final
manuscript.
Acknowledgements
The authors would also like to thank the Australian Primary Health Care
Research Institute for supporting this research. The authors are grateful to
the expert reviewers for their valuable comments, which helped improve
this article.
Received: 25 April 2014 Accepted: 6 August 2014
Published: 16 August 2014
References
1. Wang J, Christo PJ: The influence of prescription monitoring programs on
chronic pain management. Pain Physician 2009, 12(3):507–515.
2. Perrone J, Nelson LS: Medication reconciliation for controlled substances–
an “ideal” prescription-drug monitoring program. N Engl J Med 2012,
366(25):2341–2343.
3. Paulozzi LJ, Kilbourne EM, Desai HA: Prescription drug monitoring
programs and death rates from drug overdose. Pain Med 2011,
12(5):747–754.
4. Lembke A: Why doctors prescribe opioids to known opioid abusers.
N Engl J Med 2012, 367(17):1580–1581.
5. Katz MH: Long-term opioid treatment of nonmalignant pain: a believer
loses his faith. Arch Intern Med 2010, 170(16):1422–1424.
6. Office of Substance Abuse and Mental Health Services: 2013 Prescription
Monitoring Program Survey Results. USA: Maine Department of Health and
Human Services; 2013.
7. Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P:
A statewide prescription monitoring program affects emergency
department prescribing behaviors. Ann Emerg Med 2010,
56(1):19–23. e11-13.
8. Yokell MA, Green TC, Rich JD: Prescription drug monitoring programs.
JAMA 2012, 307(9):912. author reply 912–913.
9. Fishman SM: Commentary in Response To Paulozzi et al.: prescription
drug abuse and safe pain management. Pharmacoepidemiol Drug Saf
2006, 15:628–631.
10. Fishman SM, Heit H, Covington E, Passik SD, Rich BA, Bolen J, Rowe W: The
DEA and pain medicine-commentary series. Pain Med 2006, 7(1):71–88.
11. Turk DC, Brody MC, Okifuji EA: Physicians’ attitudes and practices
regarding the long-term prescribing of opioids for non-cancer pain.
Pain 1994, 59(2):201–208.
12. Institute of Medicine: Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education, and Research. Washington, DC: The National
Academies Press; 2011.
13. Ross-Degnan D, Simoni-Wastila L, Brown JS, Gao X, Mah C, Cosler LE,
Fanning T, Gallagher P, Salzman C, Shader RI, Inui TS, Soumerai SB:
A controlled study of the effects of state surveillance on indicators ofproblematic and non-problematic benzodiazepine use in a Medicaid
population. Int J Psychiatry Med 2004, 34(2):103–123.
14. Nist JB: Liability for overprescription of controlled substances. Can it be
justified in light of the current practice of undertreating pain? J Leg Med
2002, 23(1):85–113.
15. Finklea KM, Bagalman E, Sacco LN: Prescription Drug Monitoring
Programs. In Congressional Research Service; 2013. Available at: http://
www.fas.org/sgp/crs/misc/R42593.pdf.
16. Brushwood DB: Maximizing the value of electronic prescription
monitoring programs. J Law Med Ethics 2003, 31(1):41–54.
17. Cook L, Sefcik E, Stetina P: Pain management in the addicted population:
A case study comparison of prescriptive practice. J Addict Nurs 2004,
15:11–14.
18. Nielsen S, Bruno R: Pharmacuetical drugs: The delicate balance between
reducing pain and reducing harm. Drug Alcohol Rev 2011, 30:233–235.
19. Opioid abuse crackdown puts heroin back in style. Available at: http://
www.amednews.com/article/20130610/health/130619981/2/.
20. Crozier MK, McMillan S, Hudson S, Jones S: The eastern north carolina
opioid prescribers project: a model continuing medical education
workshop. J Opioid Manag 2010, 6(5):359–364.
21. Proposed changes to Florida prescription drug database under fire.
Available at: http://www.palmbeachpost.com/news/news/state-regional-
govt-politics/proposed-changes-to-florida-prescription-drug-data/nZdxP/.
22. AMA Advocacy Resource Center: Drug Diversion and Prescription Drug
Monitoring Programs. 2012, Available at: http://www.ama-assn.org/resources/
doc/washington/issue-brief-prescription-drug-abuse-and-diversion.pdf.
23. Public Policy Statement on Measures to Counteract Prescription Drug




24. American Medical Association: Issue brief: Rx drug abuse and diversion. AMA
recommends a comprehensive approach to national crisis. 2013, Available
at: http://www.ama-assn.org/resources/doc/washington/issue-brief-
prescription-drug-abuse-and-diversion.pdf; Accessed on 24 February 2013.
25. Ostrom CM: New prescription monitoring draws complaints. In USA:
Seattle Times; 2012. Available at: http://seattletimes.com/html/localnews/
2017147316_prescriptions04m.html, accessed on 25 Feb 2014.
26. Brogan D, Kelsall J: A harm reductionist response. Drug Alcohol Rev 2011,
30(3):330–331.
27. Institute of Medicine: Relieving Pain in America A Blueprint for
Transforming Prevention, Care, Education, and Research Chronic. In




28. Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM, Ross S, Gerhard
GS, Stewart WF: Prevalence of prescription opioid-use disorder among
chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic
criteria. J Addict Dis 2011, 30(3):185–194.
29. Ling W, Mooney L, Hillhouse M: Prescription opioid abuse, pain and
addiction: clinical issues and implications. Drug Alcohol Rev 2011,
30(3):300–305.
30. Clark T, Eadie J, Kreiner P, Strickler G: Prescription Drug Monitoring
Programs: An Assessment of the Evidence for Best Practices. In The
Prescription Drug Monitoring Program Center of Excellence. Brandeis
University: Heller School for Social Policy and Management; 2012.
31. McDonald DC, Carlson KE: Estimating the prevalence of opioid diversion
by “doctor shoppers” in the United States. PLoS One 2013, 8(7):e69241.
32. Blumenschein K, Fink J, Freeman P, James K, Kirsh K, Steinke DJT: Review of
Prescription Drug Monitoring Programs in the United States: Independent
Evaluation of the KASPER Program. Lexington, Kentucky: University of
Kentucky; 2010.
33. Slevin KA, Ashburn MA: Primary care physician opinion survey on FDA
opioid risk evaluation and mitigation strategies. J Opioid Manag 2011,
7(2):109–115.
34. Young A, Alfred KC, Davignon PP, Hughes LM, Robin LA, Chaudhry HJ:
Physician survey examining the impact of an educational tool for
responsible opioid prescribing. J Opioid Manag 2012, 8(2):81–87.
35. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN, Canadian Drug
S, Effectiveness Research N: Effect of a centralized prescription network
Islam and McRae BMC Pharmacology and Toxicology 2014, 15:46 Page 7 of 7
http://www.biomedcentral.com/2050-6511/15/46on inappropriate prescriptions for opioid analgesics and
benzodiazepines. CMAJ 2012, 184(16):E852–856.
36. Silversides A: Australia moves to combat the misuse of prescription
opioids. BMJ 2011, 342:d1345.
37. American Society of Addiction Medicine: Public Policy Statement on
Measures to Counteract Prescription Drug Diversion, Misuse and Addiction.
In 2012. Available at: http://www.asam.org/advocacy/find-a-policy-statement/
view-policy-statement/public-policy-statements/2012/01/26/measures-to-
counteract-prescription-drug-diversion-misuse-and-addiction.
38. Report to the Subcommittee on Oversight and Investigations, Committee on
Energy and Commerce, House of Representatives: Prescription Drugs: State
Monitoring Programs Provide Useful Tool to Reduce Diversion. United States
General Accounting Office, Washington, D.C: 2002. Report: GAO-02-634.
39. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P,
Friedmann PD: How does use of a prescription monitoring program
change medical practice? Pain Med 2012, 13(10):1314–1323.
40. Fischer B, Jones W, Krahn M, Rehm J: Differences and over-time changes
in levels of prescription opioid analgesic dispensing from retail pharma-
cies in Canada, 2005–2010. Pharmacoepidemiol Drug Saf 2011,
20(12):1269–1277.
41. Simeone R, Holland L, Simeone Associates Inc: An Evaluation of
Prescription Drug Monitoring Programs. In Simeone Associates Inc; 2006.
Available at: http://www.simeoneassociates.com/simeone3.pdf.
42. Fischer B, Jones W, Urbanoski K, Skinner R, Rehm J: Correlations between
prescription opioid analgesic dispensing levels and related mortality and
morbidity in Ontario, Canada, 2005–2011. Drug Alcohol Rev 2014,
33(1):19–26.
43. Larance B, Ambekar A, Azim T, Murthy P, Panda S, Degenhardt L, Mathers B:
The availability, diversion and injection of pharmaceutical opioids in
South Asia. Drug Alcohol Rev 2011, 30(3):246–254.
44. Hall W, Degenhardt L: Regulating opioid prescribing to provide access to
effective treatment while minimizing diversion: an overdue topic for
research. Addiction 2007, 102(11):1685–1688.
doi:10.1186/2050-6511-15-46
Cite this article as: Islam and McRae: An inevitable wave of prescription
drug monitoring programs in the context of prescription opioids: pros,
cons and tensions. BMC Pharmacology and Toxicology 2014 15:46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
